Holding(s) in Company

 

Notification of major interests in shares

 

LONDON, 19 October 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:

 

1

Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached

Hikma Pharmaceuticals PLC

 

 

2	Reason for the notification
	An acquisition or disposal of voting rights	Yes
	An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached	No
	An event changing the breakdown of voting rights	No
	Other (please specify): Compliance with the Transparency Directive	No

 

 

3	Full name of the person subject to the notification obligation						FMR LLC
4	Full name of shareholders						See Section 9
5	Date of the Transaction (and date on which the threshold crossed is reached differently)						15th October 2015
6	Date on which the issuer notified						16th October 2015
7	Threshold that is crossed						5%
8	Notified details						See A, B & C below
A. Voting rights attached to shares
Class type of shares (if possible using the ISIN code)		Situation previous to the triggering transaction		Resulting situation after the triggering transaction
		Number of shares	Number of voting rights	Number of shares		Number of voting rights			% of voting rights
				Direct	Indirect	Direct		Indirect	Direct	Indirect
Ordinary Shares (0.10 GBP) GB00B0LCW083		10,012,619	10,012,619		9,940,020			9,940,020		4.98%

 

B. Qualifying Financial instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration Date	Exercise/Conversion Period/Date	Number of voting rights that may be acquired if the instrument if exercised/converted	% of voting rights
-	-	-	-	-

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Exercise Price	Expiration Date	Exercise/Conversion Period/Date	Number of voting rights instrument refers to	% of voting rights
					Nominal	Delta
-	-	-	-	-	-	-

 

Total A+B+C
Number of Voting rights	% of voting rights
9,940,020	4.98

 

9

Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable

Custodian Day to Day IM Total BANK OF NEW YORK BRUSSELS (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 8,485 BANK OF NEW YORK MELLON PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 126,481 BROWN BROTHERS HARRIMAN AND CO FMRC-FMR CO., INC 62,684 FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED 45,683 PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 65,599 PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 701,393 CIBC MELLON TRUST (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 13,333 CITIBANK NA, HONG KONG BR (S) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 16,382 JP MORGAN, BOURNEMOUTH (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 9,809 PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 147,035 JPMORGAN CHASE BANK FMRC-FMR CO., INC 3,738,352 FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED 151,087 PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 44,698 PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 66,040 MELLON BANK NA (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 318,448 NATIONAL ASTL BK MELBOURNE (S) PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 57,922 NATIONAL BANK TRUST (C) PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 14,829 NOMURA TRUST AND BANKING (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 670 NORTHERN TRUST CO (C) FMRC-FMR CO., INC 188,816 FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED 2,598,333 PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 42,554 PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 303,271 STATE STREET BANK AND TR CO FMRC-FMR CO., INC 225,374 PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 554,286 PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 438,456 Grand Total 9,940,020

 

Proxy Voting
10	Name of the proxy holder	FMR LLC
11	Number of voting rights proxy holder will cease to hold	72,599
12	Date on which proxy holder will cease to hold voting rights	15th October 2015

 

13	Additional Information
14	Contact name:	Peter Speirs, Company Secretary
15	Contact telephone number:	020 7399 2772

 

- ENDS -

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.